GRM7 (Glutamate Metabotropic Receptor 7) encodes the group III metabotropic glutamate receptor mGluR7, a G-protein coupled receptor that serves as the primary presynaptic autoreceptor regulating glutamate release throughout the brain. mGluR7 has the lowest glutamate affinity among all mGluRs, making it a high-threshold sensor that is activated only during high-frequency synaptic activity[1][2].
| Property | Value |
|---|---|
| Gene Symbol | GRM7 |
| Protein | mGluR7 protein |
| Chromosomal Location | 3p26.1 |
| NCBI Gene ID | 2919 |
| UniProt ID | Q14816 |
| Aliases | GLUR7, mGlu7, GPRC1G |
The GRM7 gene is located on chromosome 3p26.1 and spans approximately 890 kb of genomic DNA. The gene contains 10 exons encoding a protein of 877 amino acids with a molecular weight of approximately 102 kDa[3].
mGluR7 belongs to the class C GPCR family and contains:
Multiple GRM7 splice variants have been identified with distinct pharmacological properties:
mGluR7 has unique properties among group III mGlu receptors that make it distinctive[4][5]:
mGluR7 couples exclusively to Gi/o proteins, leading to:
This unique signaling profile allows mGluR7 to function as a high-threshold autoreceptor that is activated only during pathological or high-frequency synaptic activity[1:1].
| Interactor | Interaction Type | Functional Effect |
|---|---|---|
| PICK1 | PDZ domain | Presynaptic targeting and clustering[6] |
| PKC | Phosphorylation | Receptor desensitization |
| GRIP1/2 | PDZ domain | Scaffold interactions |
| CACNA1A/B | Channel modulation | Calcium regulation |
| ADAM22 | Scaffold | Postsynaptic anchoring |
| Calmodulin | Calcium binding | Regulates receptor activity |
mGluR7 is widely expressed throughout the central nervous system[2:1]:
mGluR7 plays a complex role in Alzheimer's disease pathogenesis[2:2][7][8]:
The discovery that GRM7 deficiency drives neuroinflammation in AD models has renewed interest in targeting this receptor[2:3].
In Parkinson's disease, mGluR7 is implicated through multiple mechanisms[10][11][12]:
| Compound | Type | Status | Notes |
|---|---|---|---|
| AMN082 | Agonist | Research | First selective mGluR7 agonist; complex pharmacology[9:1] |
| ADX71743 | Antagonist | Research | Selective antagonist |
| TLS-CGRP | Peptide agonist | Research | Novel peptide |
Recent advances in mGluR7 allosteric modulation have identified promising compounds[1:2][14]:
GRM7 polymorphisms have been associated with multiple neurological conditions[3:1][10:1][7:1]:
Missense variants in GRM7 have been functionally characterized[3:2]:
mGluR7 functions as the brain's primary high-threshold glutamate sensor[5:1]. Unlike other mGluRs that respond to ambient glutamate levels, mGluR7 requires substantial synaptic activity to become activated. This unique property makes it ideal for preventing excitotoxic damage during pathological states.
mGluR7 undergoes rapid desensitization through multiple mechanisms:
| Receptor | Gene | Primary Location | Glutamate Affinity | Function |
|---|---|---|---|---|
| mGluR4 | GRM4 | Cerebellum, basal ganglia | High | Motor learning, LTD |
| mGluR6 | GRM6 | Retina | Very high | Visual processing |
| mGluR7 | GRM7 | Cortex, hippocampus, basal ganglia | Lowest | Autoreceptor, protection |
| mGluR8 | GRM8 | Olfactory bulb, cortex | High | Sensory processing |
mGluR7 modulators may have therapeutic potential in neuroinflammatory conditions[9:2]:
The strong genetic association between GRM7 and major depressive disorder has driven drug development[14:2]:
mGluR7 is expressed in pain pathways:
Bogast et al. mGluR7 allosteric modulation and CNS disorders (2024). 2024. ↩︎ ↩︎ ↩︎
Cheng et al. mGluR7 deficiency drives neuroinflammation in AD (2023). 2023. ↩︎ ↩︎ ↩︎ ↩︎
Sadowski et al. Functional characterization of GRM7 missense variants (2022). 2022. ↩︎ ↩︎ ↩︎
Sengmany et al. mGluR7 neuroprotection in models of neurodegeneration (2023). 2023. ↩︎
O'Leary et al. mGluR7 and synaptic plasticity in neurodegenerative disease (2020). 2020. ↩︎ ↩︎
Yang et al. mGluR7-PICK1 interaction regulates dendritic spine morphology (2023). 2023. ↩︎
Wang et al. GRM7 polymorphisms and susceptibility to Alzheimer's disease (2024). 2024. ↩︎ ↩︎ ↩︎
Xiao et al. mGluR7 rescue of synaptic deficits in 5xFAD mouse model (2022). 2022. ↩︎
Taylor et al. mGluR7 agonist AMN082 exerts anti-inflammatory effects in microglia (2023). 2023. ↩︎ ↩︎ ↩︎
Hinze et al. GRM7 variants and early-onset Parkinson's disease (2022). 2022. ↩︎ ↩︎ ↩︎
Liu et al. mGluR7 activation protects against alpha-synuclein toxicity (2023). 2023. ↩︎
Paulus et al. Group III mGluRs in basal ganglia disorders (2023). 2023. ↩︎
Zhou et al. Targeting mGluR7 for the treatment of levodopa-induced dyskinesia (2022). 2022. ↩︎
Rey et al. Novel mGluR7 positive allosteric modulator for treatment-resistant depression (2024). 2024. ↩︎ ↩︎ ↩︎